Ionis Pharmaceuticals (IONS) Tops Q4 EPS by 45c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Raymond James
February 20, 2025 5:50 AM ESTRaymond James analyst Gary Nachman lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $61.00) while maintaining a Strong Buy rating.
The analyst comments "Key Updates. 1) Wainua in ATTR-PN. AZN booked $42M in 4Q (+83% q/q; FY $86M), with ~$10M royalties to IONS (FY $20M). U.S. launch is progressing well with new-to-brand share ~40%; seeing good... More
